AI assistant
CEMTREX INC — Regulatory Filings 2021
Feb 11, 2021
34786_rns_2021-02-11_91bdc55a-f782-4ccf-bc61-13bcc31af3d4.zip
Regulatory Filings
Open in viewerOpens in your device viewer
8-K 1 form8-k.htm
Field: Rule-Page
Field: /Rule-Page
United States
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Field: Rule-Page
Field: /Rule-Page
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2021
Cemtrex Inc. (Exact name of registrant as specified in its charter)
| Delaware | 001-37464 | 30-0399914 |
|---|---|---|
| (State | ||
| or other jurisdiction of | ||
| incorporation) | (Commission File | |
| Number) | (I.R.S. | |
| Employer Identification | ||
| No.) |
| 276 Greenpoint Ave Bld. 8 Suite 208 Brooklyn,
| NY | 11101 |
|---|---|
| (Address | |
| of principal executive offices) | (Zip |
| Code) |
Registrant’s telephone number, including area code: (631) 756-9116
Field: Rule-Page
Field: /Rule-Page
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425) | | --- | --- | | [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | | [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | | [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol | Name of each exchange on which registered | | --- | --- | --- | | Common Stock | CETX | Nasdaq Capital Market | | Series 1 Preferred Stock | CETXP | Nasdaq Capital Market | | Series 1 Warrants | CETXW | Nasdaq Capital Market |
Field: Rule-Page
Field: /Rule-Page
Field: Page; Sequence: 1
Field: /Page
CURRENT REPORT ON FORM 8-K
Cemtrex, Inc.
February 10, 2021
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On February 8, 2021, Cemtrex, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because of the resignation of Raju Panjwani from the Company’s board and audit committee, effective January 25, 2021, the Company no longer complies with Nasdaq’s audit committee requirements as set forth in Listing Rule 5605.
The notification letter also disclosed that Nasdaq will provide the Company a cure period in order to regain compliance as follows:
| ● | until the earlier of the Company’s next annual shareholders’ meeting or January 25, 2022; or | | --- | --- | | ● | if the next annual shareholders’ meeting is held before July 26, 2021, then the Company must evidence compliance no later than July 26, 2021. |
The Company intends to have a replacement for Mr. Panjwani’s seat on the board and the audit committee prior to the expiration of the cure period.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit Number | Exhibit Title | | --- | --- | | 99.1 | Notice of Failure to Satisfy a Continued Listing Rule from NASDAQ Dated February 8, 2021 |
Field: Page; Sequence: 2
Field: /Page
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| /s/
| Saagar Govil |
|---|
| Saagar |
| Govil |
| Chairman, |
| President and Chief Executive Officer |
Field: Page; Sequence: 3; Options: Last
Field: /Page